a good activator of PKB/Akt but not of mitogen-activated protein (MAP) kinase, failed to induce endogenous BAD phosphorylation, although it did promote survival. In addition, both IL-3 and ...

Interestingly, they observed that phosphorylation of a specific regulator called ARHGEF2 led to the activation of RhoA, which ...

The changes in phosphorylation states of key proteins ... cancer types that were reliant on PI3K/AKT/mTOR and similar protein kinase pathways for growth and survival.

Treatment options for patients with esophageal squamous cell carcinoma (ESCC) often result in poor prognosis and declining ...

Cirtuvivint is under clinical development by Biosplice Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

Cirtuvivint is under clinical development by Biosplice Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.